Stephen Kinnock

Stephen Kinnock

Labour — Aberafan Maesteg

Speaking in the House of Commons on 23 July 2024

Debate

Topical Questions

Contribution

I thank my hon. Friend for that question and welcome him to his place. This issue is personal for me, and I am sure it is for many others across this House. A number of potential new disease-modifying drugs for Alzheimer’s are in the pipeline, including lecanemab and donanemab. We are committed to ensuring that clinically effective and cost-effective medicines reach patients in a timely and safe way. The National Institute for Health and Care Excellence is appraising lecanemab and donanemab to determine whether they will be made available in the NHS.

More from Stephen Kinnock

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Stephen Kinnock's full parliamentary record including voting history, expenses and all other contributions, see the Stephen Kinnock report card.